Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myocarditis 1Multiple Pulmonary Nodules 1Liver Metastases 1Hematologic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

pembrolizumab 45Specimen Handling 45Biopsy 37Magnetic Resonance Spectroscopy 36Paclitaxel 22Nivolumab 21Carboplatin 21Gemcitabine 20Radiosurgery 18Irinotecan 16Ipilimumab 13Cisplatin 13Capecitabine 12130-nm albumin-bound paclitaxel 12trastuzumab deruxtecan 11Taxes 11Pemetrexed 11Cetuximab 11olaparib 10Leucovorin 10Fluorouracil 10Cyclophosphamide 10durvalumab 9Oxaliplatin 9Bevacizumab 9abemaciclib 8X-Rays 8Fulvestrant 8Drug Therapy 8palbociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Positron Emission Tomography Computed Tomography × 90 days × Clear all
NCT06067503 2026-04-13

Biomarkers to Detect Endocrine Therapy Resistance

University of Wisconsin, Madison

Phase 2 Recruiting
8 enrolled
Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡